Guardant Health (GH)
Nasdaq Market Closed
Guardant Health, Inc. is a precision oncology company that develops blood-based tests designed to support cancer care across screening, diagnosis, treatment selection, and monitoring. Headquartered in Redwood City, California, the company is best known for applying liquid biopsy technology to detect and analyze fragments of tumor DNA that circulate in the bloodstream. This approach can offer clinicians genomic information when tissue samples are difficult to obtain or when repeated testing is needed over the course of a patient’s disease.
The company’s core commercial portfolio includes Guardant360, a comprehensive genomic profiling test used to help identify actionable mutations in patients with advanced cancer. Guardant Reveal is aimed at molecular residual disease and recurrence monitoring, while Shield is Guardant Health’s blood-based colorectal cancer screening product. Together, these franchises place the company across several large markets in oncology, from therapy selection to early detection.
Guardant Health also works with pharmaceutical and biotechnology companies by providing research services, companion diagnostic development, clinical trial support, and data-driven insights for oncology drug development. Its tests are used in clinical practice and research settings, giving the business exposure to both healthcare providers and life sciences partners.
For investors, Guardant Health represents a healthcare technology stock tied to the growth of precision medicine, cancer screening, and minimally invasive diagnostics. Its long-term opportunity depends on test adoption, reimbursement coverage, clinical evidence, regulatory progress, and competition from other diagnostic platforms.
Last updated
- Market Cap
- 17.64B
- P/E
- —
- P/FCF
- —
- P/S
- 16.33
- Enterprise Value
- 18.16B
- Sector
- Health Care
- Industry
- Medical Laboratories
- Address
- 3100 HANOVER STREET, PALO ALTO, CA, 94304
AI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market Globally
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights
Pre-Dx Oncology Market Outlook 2026–2035: A Strategic Insight by Towards Healthcare
Oncology Biomarker Market Accelerates Toward USD 113.5 Billion by 2034
Breast Cancer Screening Tests Market to Reach USD 8.77 Billion by 2034, Shows Steady 7.04% CAGR
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research
Guardant Health (GH) Just Overtook the 20-Day Moving Average
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 17.64B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 18.16B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -97.44
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 16.33
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -44.44
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 16.81
- EPS
- -3.27
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -237.12M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 239.24%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -22.62%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- -8.3
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.68
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.39
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.39
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.28M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 133.06
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 301.67M | 281.27M | 265.2M | 232.09M | 203.47M |
| Gross profit | 196.75M | 181.77M | 171.61M | 150.88M | 128.75M |
| Operating income | -121.35M | -120.81M | -98.99M | -106.41M | -111.04M |
| EBITDA | -111.91M | -110.76M | -89.58M | -96.37M | -100.81M |
| Net income | -112.08M | -128.49M | -92.73M | -99.9M | -95.16M |
| Basic EPS | -0.85 | -1 | -0.74 | -0.8 | -0.77 |
| Diluted EPS | -0.85 | -1 | -0.74 | -0.8 | -0.77 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.92B | 2.01B | 1.28B | 1.33B | 1.34B |
| Total liabilities | 2.1B | 2.11B | 1.63B | 1.64B | 1.6B |
| Total equity | -181.07M | -99.31M | -354.47M | -305.48M | -250.79M |
| Cash & equivalents | 989.29M | 378.2M | 580.01M | 629.14M | 698.57M |
| Current assets | 1.37B | 1.47B | 828.89M | 883.43M | 927.03M |
| Current liabilities | 292.15M | 302.73M | 236.92M | 238.43M | 225.75M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -65.62M | -26.37M | -35.41M | -60.29M | -62.69M |
| Investing cash flow | 699.42M | -905.07M | -14.35M | -10.65M | 302.86M |
| Financing cash flow | -21.58M | 732.03M | 4.33M | 1.62M | -66.85M |
| Change in cash | 612.02M | -200.1M | -45.97M | -68.37M | 174.1M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Krognes Steve E. | View Filing | |
| form 4 | Form 4 — Krognes Steve E. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| form 4 | Form 4 — Saia John G. | View Filing | |
| form 4 | Form 4 — Saia John G. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Freeman Chris | View Filing | |
| form 4 | Form 4 — Freeman Chris | View Filing | |
| form 4 | Form 4 — Freeman Chris | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — CLARK IAN T | View Filing | |
| form 4 | Form 4 — Saia John G. | View Filing | |
| form 4 | Form 4 — Saia John G. | View Filing | |
| form 4 | Form 4 — Saia John G. | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Tariq Musa | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing | |
| edgar index | SCHEDULE 13G — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Tariq Musa | View Filing | |
| form 4 | Form 4 — Tariq Musa | View Filing | |
| form 4 | Form 4 — Chudova Darya | View Filing | |
| form 4 | Form 4 — Chudova Darya | View Filing | |
| form 4 | Form 4 — Chudova Darya | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| edgar index | 144 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Talasaz AmirAli | View Filing | |
| edgar index | 8-K — Guardant Health, Inc. | View Filing | |
| edgar index | 10-Q — Guardant Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Krognes Steve E. | View Filing | |
| form 4 | Form 4 — Krognes Steve E. | View Filing | |
| edgar index | DEF 14A — Guardant Health, Inc. | View Filing | |
| edgar index | DEFA14A — Guardant Health, Inc. | View Filing | |
| edgar index | ARS — Guardant Health, Inc. | View Filing | |
| edgar index | 8-K — Guardant Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — MIGNONE ROBERTO | View Filing | |
| form 4 | Form 4 — MIGNONE ROBERTO | View Filing | |
| edgar index | 4 — Guardant Health, Inc. | View Filing | |
| form 4 | Form 4 — Hidalgo Medina Manuel | View Filing |